Drug intelligence / Profile preview

608

Development stage: Phase 3
Lead developer: 3SBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous Injection[3]

Overview

"608" is a code name that refers to multiple drugs depending on the context. The most prominent and current reference in drug development is to a recombinant, humanized anti-interleukin-17A monoclonal antibody developed by 3SBio and Sunshine Guojian Pharmaceutical. This biologic acts as an IL-17A protein inhibitor and is being investigated for inflammatory diseases, particularly plaque psoriasis (Phase III) and axial spondyloarthritis (Phase II). It belongs to the class of anti-inflammatories, antirheumatics, monoclonal antibodies, and skin disorder therapies. Its mechanism involves blocking interleukin-17A activity, thereby reducing inflammation associated with autoimmune conditions[3].

Other names: 608

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on 608.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 608.

Explore the full profile